SpectraCure Management
Management criteria checks 3/4
SpectraCure's CEO is Masoud Khayyami, appointed in Jan 2023, has a tenure of 2.67 years. directly owns 21.45% of the company’s shares, worth €4.40M. The average tenure of the management team and the board of directors is 5 years and 2.7 years respectively.
Key information
Masoud Khayyami
Chief executive officer
SEK 300.0k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 2yrs |
| CEO ownership | 21.5% |
| Management average tenure | 5yrs |
| Board average tenure | 2.7yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -SEK 23m |
| Jun 30 2024 | n/a | n/a | -SEK 21m |
| Mar 31 2024 | n/a | n/a | -SEK 21m |
| Dec 31 2023 | SEK 300k | n/a | -SEK 20m |
| Sep 30 2023 | n/a | n/a | -SEK 23m |
| Jun 30 2023 | n/a | n/a | -SEK 23m |
| Mar 31 2023 | n/a | n/a | -SEK 24m |
| Dec 31 2022 | SEK 300k | n/a | -SEK 25m |
| Sep 30 2022 | n/a | n/a | -SEK 25m |
| Jun 30 2022 | n/a | n/a | -SEK 25m |
| Mar 31 2022 | n/a | n/a | -SEK 25m |
| Dec 31 2021 | SEK 2m | SEK 1m | -SEK 23m |
Compensation vs Market: Masoud's total compensation ($USD26.90K) is below average for companies of similar size in the German market ($USD464.61K).
Compensation vs Earnings: Masoud's compensation has been consistent with company performance over the past year.
CEO
Masoud Khayyami (61 yo)
2yrs
Tenure
SEK 300,000
Compensation
Dr. Masoud Khayyami, Ph D., serves as Nomination Committee Member of Lumito AB (publ). He is a Founder and serves as Manager at MK Capital AB.He served as Chairman of the Board of Lumito AB (publ) until 2...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Interim CEO & Director | 2yrs | SEK 300.00k | 21.45% € 4.4m | |
| Chief Financial Officer | 7yrs | no data | no data | |
| Chief Technology Officer | 16yrs | no data | no data | |
| Administrative Manager | no data | no data | no data | |
| Head of Clinical Affairs | 3yrs | no data | no data |
5.0yrs
Average Tenure
59yo
Average Age
Experienced Management: 2OK's management team is seasoned and experienced (5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Interim CEO & Director | 2.7yrs | SEK 300.00k | 21.45% € 4.4m | |
| KhayyamiScientific Advisors | no data | no data | no data | |
| Independent Director | 3.7yrs | SEK 300.00k | no data | |
| Independent Director | 22yrs | SEK 300.00k | 0.21% € 42.3k | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data | |
| Independent Director | 2.7yrs | SEK 300.00k | 0.026% € 5.3k | |
| Independent Chairman of the Board | 2.7yrs | SEK 500.00k | 1.51% € 310.3k | |
| Independent Director | 2.7yrs | SEK 600.00k | 0.0046% € 950.0 |
2.7yrs
Average Tenure
65.5yo
Average Age
Experienced Board: 2OK's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/08 03:00 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
SpectraCure AB (publ) is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Markus Augustsson | Carlsquare AB |